News Update: Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer - Thomas Keane

(Length of Update: 4 min)

As we start a new year, Dr. Thomas Keane provides an update on exciting news in the area of non-metastatic castration-resistant prostate cancer with the FDA granting priority review for apalutamide as a treatment for non-metastatic castration-resistant prostate cancer.  Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.

Watch Video from Charles Ryan, MD:
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer

Read the Press Release

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS